| Edoxaban versus warfarin in patients with atrial fibrillation RP Giugliano, CT Ruff, E Braunwald, SA Murphy, SD Wiviott, JL Halperin, ... New England Journal of Medicine 369 (22), 2093-2104, 2013 | 5801 | 2013 |
| Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve‐month data from a twenty‐four–month phase III randomized radiographic study D Van Der Heijde, Y Tanaka, R Fleischmann, E Keystone, J Kremer, ... Arthritis & Rheumatism 65 (3), 559-570, 2013 | 632 | 2013 |
| Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised … PJ Mease, D van der Heijde, CT Ritchlin, M Okada, RS Cuchacovich, ... Annals of the rheumatic diseases 76 (1), 79-87, 2017 | 579 | 2017 |
| Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial P Ponikowski, BA Kirwan, SD Anker, T McDonagh, M Dorobantu, ... The Lancet 396 (10266), 1895-1904, 2020 | 560 | 2020 |
| Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial HJL Heerspink, HH Parving, DL Andress, G Bakris, R Correa-Rotter, ... The Lancet 393 (10184), 1937-1947, 2019 | 488 | 2019 |
| Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial J Vestbo, JA Anderson, RD Brook, PMA Calverley, BR Celli, C Crim, ... The Lancet 387 (10030), 1817-1826, 2016 | 486 | 2016 |
| Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an … R Fleischmann, M Cutolo, MC Genovese, EB Lee, KS Kanik, S Sadis, ... Arthritis & Rheumatism 64 (3), 617-629, 2012 | 449 | 2012 |
| A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid … JM Kremer, S Cohen, BE Wilkinson, CA Connell, JL French, ... Arthritis & Rheumatism 64 (4), 970-981, 2012 | 393 | 2012 |
| Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial) D Isenberg, C Gordon, D Licu, S Copt, CP Rossi, D Wofsy Annals of the rheumatic diseases 74 (11), 2006-2015, 2015 | 308 | 2015 |
| Three multicenter, randomized, double‐blind, placebo‐controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis A Deodhar, LS Gensler, J Sieper, M Clark, C Calderon, Y Wang, Y Zhou, ... Arthritis & Rheumatology 71 (2), 258-270, 2019 | 291 | 2019 |
| A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised … PJ Mease, JS Smolen, F Behrens, P Nash, SL Leage, L Li, H Tahir, ... Annals of the rheumatic diseases 79 (1), 123-131, 2020 | 279 | 2020 |
| A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy P Emery, J Vencovský, A Sylwestrzak, P Leszczyński, W Porawska, ... Annals of the rheumatic diseases 76 (1), 51-57, 2017 | 279 | 2017 |
| Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY … KK Ray, HM Colhoun, M Szarek, M Baccara-Dinet, DL Bhatt, VA Bittner, ... The lancet Diabetes & endocrinology 7 (8), 618-628, 2019 | 246 | 2019 |
| Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose … A Kavanaugh, J Kremer, L Ponce, R Cseuz, OV Reshetko, ... Annals of the rheumatic diseases 76 (6), 1009-1019, 2017 | 238 | 2017 |
| Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double‐blind, placebo‐controlled trials MEB Clowse, DJ Wallace, RA Furie, MA Petri, MC Pike, P Leszczyński, ... Arthritis & rheumatology 69 (2), 362-375, 2017 | 221 | 2017 |
| Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled … P Mease, LC Coates, PS Helliwell, M Stanislavchuk, ... The Lancet 392 (10162), 2367-2377, 2018 | 201 | 2018 |
| Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo … DL Bhatt, PG Steg, SR Mehta, LA Leiter, T Simon, K Fox, C Held, ... The Lancet 394 (10204), 1169-1180, 2019 | 200 | 2019 |
| A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid … JY Choe, N Prodanovic, J Niebrzydowski, I Staykov, E Dokoupilova, ... Annals of the Rheumatic Diseases 76 (1), 58-64, 2017 | 193 | 2017 |
| Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo‐controlled trial RF Van Vollenhoven, N Kinnman, E Vincent, S Wax, J Bathon Arthritis & Rheumatism 63 (7), 1782-1792, 2011 | 189 | 2011 |
| Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3 … ME Weinblatt, CO Bingham, AM Mendelsohn, L Kim, M Mack, J Lu, ... Annals of the rheumatic diseases 72 (3), 381-389, 2013 | 135 | 2013 |
